ArticleJournal of neuro-oncology2005
Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
Article in Journal of neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative molecular profiles of distinct tumor components in recurrent tentorial meningioma after stereotactic radiosurgery: a case report implicating acquired aggressive alterations associated with WHO grade progression.Brain tumor pathology · 2026Article
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.Journal of neuro-oncology · 2023Article
- Use of Handheld Raman Spectroscopy for Intraoperative Differentiation of Normal Brain Tissue From Intracranial Neoplasms in Dogs.Frontiers in veterinary science · 2021Article
- Long-term follow-up of surgical resection alone for primary intracranial rostrotentorial tumors in dogs: 29 cases (2002-2013).Open veterinary journal · 2017Article
- Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.Neuro-oncology · 2013Article
- Surgical Outcome of Treating Grades II and III Meningiomas: A Report of 32 Cases.Neuroscience journal · 2013Article
- Growth curve analysis of asymptomatic and symptomatic meningiomas.Journal of neuro-oncology · 2011Article
- Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.Journal of neuro-oncology · 2011Article
- DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.The oncologist · 2011Article
- Evaluation of neo-angiogenesis in a case of chordoid meningioma.Journal of neuro-oncology · 2009Article
- Loss of heterozygosity studies in extracranial metastatic meningiomas.Journal of neuro-oncology · 2007Article
- Two-Staged Approach for Giant Hypervascular Meningioma Resection.Asian journal of neurosurgeryArticle
- Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery: systematic review and meta-analysis of observational studies.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In meningioma recurrences a tumor progression has been proposed on a molecular genetic basis. From the histological point of view the problem has not been sufficiently investigated. Recurrences mainly depend on tumor location, histology, resection type and on the tumor growth in the adjacent nervous tissue. Seventy-six completely resected recurrent meningiomas have been studied. Most tumors were convexity or parasagittal meningiomas. The number of recurrences studied per tumor varied from 1 to 5. Besides histological methods, immunohistochemistry for Ki-67 MIB-1, TUNEL for apoptosis, counts of mitoses and molecular genetics for CDKN2A were performed. No variation of the mitotic index (MI) or MIB-1 labeling index (LI) was observed in recurrences. Histological features, the number of mitoses and the MIB-1 LI showed a great regional variability. Loss of heterozygosity (LOH) of CDKN2A was found to be slightly more frequent in the first recurrence than in the initial tumor, but it was lower in the following recurrences. The nervous tissue adjacent to the tumor could contain meningothelial cells and be responsible for recurrences. The number of mitoses appeared to be the most important criterion for establishing the tumor grade. The histological aspect does not change in recurrences and there is no progression. The greater number of recurrences in atypical and anaplastic tumors depends on their initial higher proliferation capacity. The occurrence of tumor meningothelial cells in the adjacent nervous tissue or in the thickened arachnoidal membrane can be responsible for recurrence.
Indexed as
Identifiers
15981101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.